This year, about 240,000 people in the U.S. will discover they have lung cancer. Some 200,000 of them will be diagnosed with non-small-cell lung cancer, which is the second leading cause of death after cardiovascular disease.
Oct 6, 2022
0
96
Northwestern Medicine scientists have identified and described a new gene that is responsible for activating an aggressive subtype of small-cell lung cancer, the P subtype, for which there is no current effective treatment.
Oct 5, 2022
0
323
Over the last decade, immune checkpoint blockers, or ICBs, have revolutionized treatment for various advanced cancers, including melanoma, the most aggressive skin cancer that was considered largely incurable not long ago. ...
Sep 19, 2022
0
67
Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting ...
Sep 13, 2022
0
65
One of the main challenges in oncology is the development of drugs against KRAS oncogenes. These oncogenes—genes that cause cancer when mutated—are responsible for a quarter of all human cancers, including the three tumor ...
Sep 1, 2022
0
34
An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. ...
Aug 31, 2022
0
115
Patients with metastatic non-small cell lung cancer who received a combined therapy of tremelimumab, durvalumab and chemotherapy experienced longer overall survival compared with those who received chemotherapy alone, regardless ...
Aug 9, 2022
0
2
In California and across the country, more people are likely to die from lung cancer than any other cancer, the American Lung Association states in an August press release, as wildfire season is in full swing.
Aug 8, 2022
0
13
A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.
Aug 8, 2022
0
5
Glioblastoma multiforme (GBM) is one of the most aggressive, fast-growing tumor types, and the most common cancer of the brain with a median overall survival of approximately 15 months. Despite recent advances in treatment ...
Aug 2, 2022
0
5
